{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-081717","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2024-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.342289+00:00","generated_at":"2026-05-31T18:08:42.402832+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kiniksa Q2 ARCALYST revenue $103.4M (+90% YoY); 2024 guidance raised to $405-415M","bullets":["ARCALYST net product revenue $103.4M in Q2 2024, up 90% YoY; ~11% of target 14,000 patients on therapy.","Total revenue $108.6M (Q2 2024) vs $71.5M (Q2 2023); net loss $3.9M vs net income $15.0M YoY.","2024 ARCALYST net revenue guidance increased to $405-415M from prior $370-390M.","Cash and investments $218.8M, no debt; expects to remain cash flow positive annually.","Phase 2b trial of abiprubart in Sjögren's Disease enrolling; clinical development fully funded."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-081717","json":"https://secwatch.observer/filing/0001104659-24-081717.json","markdown":"https://secwatch.observer/filing/0001104659-24-081717.md","text":"https://secwatch.observer/filing/0001104659-24-081717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924081717/0001104659-24-081717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924081717/tm2419915d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T18:08:42.402832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}